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Abstract: Medication-related osteonecrosis of the jaw (MRONJ) is a severe pathological condition
associated mainly with the long-term administration of bone resorption inhibitors, which are known
to induce suppression of osteoclast activity and bone remodeling. Bone Morphogenetic Protein
(BMP)-2 is known to be a strong inducer of bone remodeling, by directly regulating osteoblast
differentiation and osteoclast activity. This study aimed to evaluate the effects of BMP-2 adsorbed
onto beta-tricalcium phosphate (β-TCP), which is an osteoinductive bioceramic material and allows
space retention, on the prevention and treatment of MRONJ in mice. Tooth extraction was performed
after 3 weeks of zoledronate (ZA) and cyclophosphamide (CY) administration. For prevention studies,
BMP-2/β-TCP was transplanted immediately after tooth extraction, and the mice were administered
ZA and CY for an additional 4 weeks. The results showed that while the tooth extraction socket was
mainly filled with a sparse tissue in the control group, bone formation was observed at the apex of the
tooth extraction socket and was filled with a dense connective tissue rich in cellular components in the
BMP-2/β-TCP transplanted group. For treatment studies, BMP-2/β-TCP was transplanted 2 weeks
after tooth extraction, and bone formation was followed up for the subsequent 4 weeks under ZA
and CY suspension. The results showed that although the tooth extraction socket was mainly filled
with soft tissue in the control group, transplantation of BMP-2/β-TCP could significantly accelerate
bone formation, as shown by immunohistochemical analysis for osteopontin, and reduce the bone
necrosis in tooth extraction sockets. These data suggest that the combination of BMP-2/β-TCP could
become a suitable therapy for the management of MRONJ.
Keywords: BMP-2; MRONJ; bone regeneration
1. Introduction
In a super-aging society, the increasing number of patients with bone-resorption diseases
(e.g., osteoporosis) has become an important issue of societal concern. Bone resorption inhibitors,
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such as bisphosphonates (BP), have been widely used for not only the treatment of osteoporosis but
also suppression of bone metastatic cancer [1–4]. Rarely, however, individuals taking bone resorption
inhibitors present with medication-related osteonecrosis of the jaw (MRONJ), particularly those who
have suffered invasive dental treatments, such as tooth extraction. MRONJ is mainly characterized by
incomplete healing of oral mucosa, jaw osteonecrosis, and necrotic jaw bone exposure with increased
risk of infection, and induces significant burden and dysfunction to patients that affect the overall
individual’s health and quality of life [5–10].
Although MRONJ was first reported in 2003 by Marx [11], the cause and pathophysiological
mechanisms of MRONJ are still unclear, and the treatment method has not been clearly defined. It is
known that bone resorption inhibitors cause an excessive suppression of osteoclast activities, resulting
in the inactivation of bone remodeling and the increased susceptibility for oral bacterial infection [7–9].
Moreover, inhibition of angiogenesis is another major hypothesis in MRONJ pathophysiology since
osteonecrosis itself is classically considered an interruption in vascular supply [7].
Bone Morphogenetic Protein (BMP)-2 is known to be a strong inducer of orthotopic and ectopic
bone formation [12,13]. In the United States and Europe, the bone graft material (INFUSE®, Medtronic,
USA), which uses collagen and human recombinant BMP-2 (rhBMP-2) derived from mammalian cells,
has already been approved by the U.S. Food and Drug Administration (FDA) for clinical applications
in cases requiring bone tissue regeneration in the orthopedic and dental fields [14–17]. BMP-2 is well
known as a protein that strongly promotes osteoblast differentiation via BMP receptors [12,17,18].
On the other hand, BMP receptors have also been reported to be present in osteoclasts, and therefore,
BMP-2 is also known to directly enhance osteoclast activities and overall bone remodeling [19,20].
Moreover, the BMPs are also known to be an important factor that controls angiogenesis and blood
vessel maintenance [21]. Therefore, BMP-2 could have constructive effects on the reduced angiogenesis
condition due to bone hardening, or even MRONJ-associated bone necrosis.
Nevertheless, BMP-2 has been considered to have only a moderate effect on the prevention or
reconstruction of MRONJ-associated symptoms [22]. Moreover, Jung et al. have shown that the
combination of parathyroid hormone (PTH) and BMP-2 helped to significantly improve bone formation
compared with BMP-2 alone or a control group [23]. Additionally, a major limitation is regarding
the fact that most studies have used collagen as a carrier, which does not allow space retention.
Therefore, the utilization of bioceramics, which allow space-making, could be alternative materials for
optimization of BMP-2 function in the prevention and treatment of MRONJ.
Hydroxyapatite (HAp) was one of the first developed bone replacement materials [24]. Despite its
outstanding mechanical properties, the commercially available HAp shows no or poor resorption
ability by osteoclasts [25,26]. On the other hand, the bioceramic beta-tricalcium phosphate (β-TCP)
has been considered as an osteoconductive material that allows space retention and can be resorbed
by osteoclasts, and therefore, be replaced by new bone. Moreover, β-TCP has also been approved by
the U.S. FDA and is currently widely used for bone regeneration therapy in the fields of orthopedics
and dentistry.
In our previous preclinical study, we developed a bone substitute material using Escherichia
coli-derived rhBMP-2 (E-BMP-2) adsorbed in porous β-TCP as a carrier and succeeded in inducing
bone formation in a porcine maxillary sinus floor elevation model [27]. Importantly, E-BMP-2/β-TCP
has been recently approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for
application in bone augmentation before dental implant treatment in human clinical trials. However, it is
unclear whether BMP-2/β-TCP could be also used both in the prevention and treatment of the symptoms
related to MRONJ in humans. Therefore, the aim of this study was to evaluate the effect of BMP-2/β-TCP
on bone formation in tooth extraction sockets in MRONJ prevention and treatment models in mice.
The results demonstrated that local administration of BMP-2/β-TCP in the tooth extraction sockets
significantly induced bone formation and reduced the bone necrosis in both MRONJ-like prevention
and treatment models.
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2. Results
2.1. Transplantation of BMP-2/β-TCP Could Not Accelerate the Bone Regeneration in the Tooth Extraction
Socket during the Normal Wound Healing Process
First, in order to obtain a deeper understanding of the normal wound healing process of tooth
extraction sockets, micro computed tomography (micro-CT) and histological analyses were performed
at 1, 2 and 4 weeks after the extraction of maxillary first molars in mice. Micro-CT analysis showed
that bone was not formed in the tooth extraction socket in the first week of healing, but appeared from
the second week onward, showing an increase in density until the fourth week of healing (Figure 1A).
Hematoxyline and Eosin (HE)-based histological analysis revealed immature woven bone formation in
the tooth extraction socket at 1 week post-surgery (Figure 1B), with a bone-fill rate of 45.6% ± 11.5%
(Figure 1E). Note that the tooth extraction socket was completely covered with epithelium. In the
subsequent weeks, the tooth extraction socket was filled with new bone tissue, with a bone-fill rate of
87.1% ± 0.8% at 4 weeks post-surgery, and 91.1% ± 2.1% at 8 weeks post-surgery (data not shown).
Notably, there was no significant difference in the total amount of bone regeneration from the fourth to
the eighth week of healing. Additionally, these results indicate that the tooth extraction socket was
almost completely replaced with the new bone after 4 weeks. Therefore, the subsequent experiments
were followed up until the fourth week after tooth extraction.
Next, the effect of BMP-2/β-TCP on the normal wound healing process of tooth extraction
socket was evaluated. Micro-CT analysis showed a radiopaque area corresponding to β-TCP in
the tooth extraction socket after one and two weeks, but it was hardly distinguished at 4 weeks
after transplantation (Figure 1C). Accordingly, histological analysis confirmed the presence of β-TCP
in the tooth extraction socket after one to two weeks of transplantation (Figure 1D). Nevertheless,
after four weeks, almost no β-TCP was observed in the tooth extraction socket, and the bone-fill
rate reached 87.5% ± 3.7% (Figure 1E). Note that the area surrounding β-TCP was replaced by new
bone after the initial week. Note also that while the bone regeneration rate of BMP-2/β-TCP was
significantly low compared with normal healing in the initial week, possibly because of the slower
resorption rate of β-TCP compared to the faster rate of bone formation, the bone regeneration rate in
the BMP-2/β-TCP-transplanted group was not significantly different compared to that of the normal
healing process of the tooth extraction socket either at 2 or 4 weeks post-surgery. From the above
results, it was clarified that the transplantation of BMP-2/β-TCP could not accelerate bone regeneration
during the normal wound healing process after 2 or 4 weeks of tooth extraction.
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Sagittal images of micro-CT and (D) HE-stained sections after 1, 2 and 4 weeks of BMP-2/β-TCP 
transplantation into the tooth extraction socket of the maxillary first molar. (E) The graph shows the 
quantitative analysis of the bone-fill rate in the tooth extraction socket. Bars represent the mean values 
and standard deviation (+/− SD) (n = 3–6). (* p < 0.05, ** p < 0.01, *** p < 0.001, ns: no significant 
difference. Two-way ANOVA/Tukey). Red arrowheads indicate the residual β-TCP. Yellow dashed 
lines indicate the tooth extraction socket. 
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2.2. Transplantation of BMP-2/β-TCP Partially Induced Bone Formation in the Tooth Extraction Socket in a
Mouse Model of MRONJ Prevention
The preventive effect of BMP-2/β-TCP on MRONJ onset was evaluated using a MRONJ-like model
in mice. The experimental design is shown in Figure 2A.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 5 of 13 
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Previously, we have reported that transplantation of β-TCP alone could not induce bone formation
and that BMP-2 was required to reliably induce bone formation in a swine sinus lift model [27].
Additionally, since MRONJ is a severe clinical condition affecting bone remodeling, in this experiment,
the experimental group was transplanted with the combination of BMP-2 and β-TCP. icro-CT analysis
showed radiopaque areas corresponding to the newly-formed bone around the highly radiopaque
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area corresponding to β-TCP in the tooth extraction socket of the BMP2/β-TCP transplanted group
(Figure 2B). Note the absence of newly-formed bone in the control group.
Histological analysis revealed that the tooth extraction socket was mainly filled with a sparse
tissue with few cellular components in the control group, indicating a disordered bone healing process
(Figure 2C) On the other hand, in the BMP-2/β-TCP transplanted group, bone formation was observed
at the apex of the tooth extraction socket, and was filled with a dense connective tissue rich in cellular
components (Figure 2C). The bone-fill rate in the BMP-2/β-TCP transplanted group (32.5% ± 17.2%)
was significantly higher than that in the control group (10.3% ± 7.9%) (Figure 2D). On the other hand,
the number of empty lacunae of regenerated bone in tooth extraction sockets, which indicates the level
of bone necrosis, was significantly decreased in the group transplanted with BMP-2/β-TCP (Figure 2E).
In addition, Masson’s trichrome staining showed that the number of collagen fibers was significantly
increased in the tooth extraction socket in the BMP-2/β-TCP transplanted group compared with the
control group (Figure 2F,G).
2.3. Transplantation of BMP-2/β-TCP Strongly Induced Bone Formation in the Tooth Extraction Socket in a
Mouse Model of MRONJ Treatment
To examine the therapeutic effect of BMP-2/β-TCP on MRONJ-associated bone loss, the tooth
extraction socket was curetted two weeks after tooth extraction in a MRONJ-like model induced by
administration of CY/ZA for 3 weeks, as shown in Figure 3A. Notably, during the two-week interval
between tooth extraction and BMP-2/β-TCP transplantation, new bone tissue had not been formed,
whilst only a sparse connective tissue was present inside the tooth extraction socket before curettage
(data not shown).
To evaluate the bone formation ability of BMP-2/β-TCP, CY and ZA, which had been administered to
induce the MRONJ-like lesion for a total of 5 weeks, were withdrawn after BMP-2/β-TCP transplantation
into the curetted tooth extraction socket on week 5. Four weeks after BMP-2/β-TCP transplantation,
micro-CT and histological analyses showed that, in the BMP-2/β-TCP transplanted group, the tooth
extraction socket was almost completely filled with new bone, and the average bone-fill rate was 76.5%
± 11.5% (Figure 3B–D), which was close to that observed during normal healing of the tooth extraction
socket (Figure 1E). In contrast, in the control group, most of the tooth extraction socket was filled with
soft tissue and the average bone-fill rate was 25.2% ± 9.7% (Figure 3B–D). Note that the number of
empty lacunae was significantly lower in the BMP-2/β-TCP transplanted group (Figure 3E).
Next, immunohistochemical analysis was performed for identification of the expression of
osteopontin (OPN), a non-collagen protein secreted by osteoblasts, in the tooth extraction socket.
The results showed that the area positive for OPN was markedly larger in the BMP-2/β-TCP
transplantation group, compared with the control group (Figure 4A,B). Moreover, tartrate-resistant
acid phosphatase (TRAP)-positive osteoclasts were also observed on the surface of the regenerated
bone in the tooth extraction sockets in both the BMP-2/β-TCP transplantation and control groups,
indicating a physiological bone turn-over (Supplementary Figure S1). Furthermore, the expression
of endomucin (EMCN), which is one of the vascular endothelial cell markers, was also analyzed.
The results, however, revealed no significant difference in the positive area (percentage) of EMCN in
the tooth extraction sockets between control and BMP-2/β-TCP-transplanted groups (Figure 4C,D).
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3. Discussion
MRONJ is a critical clinical problem characterized by progressive necrosis of the jaw bone. In
2014, the American Association of Oral and Maxillofacial Surgeons (AAOMS) updated that MRONJ is
defined as an exposed bone or bone that can be probed through an intraoral or extra-oral fistula(e) in
the maxillofacial region, which does not heal within 8 weeks, and occurs in a patient who has received
a bone-modifying agent or an angiogenic inhibitor, without a history of head and neck radiation [5,7].
It is understood that MRONJ is caused by two pharmacological agents: anti-resorptive including
bisphosphonates and anti-angiogenic agents. However, the molecular and cellular mechanisms of
MRONJ onset due to the administration of these drugs are yet unclear. Inhibition of osteoclast activity
is indeed one of the main pathogeneses. Therefore, activation of bone remodeling could be one
of the targets for the treatment of MRONJ. In the present study, we evaluated the preventive and
therapeutic effects of BMP-2, which is well known to be a powerful osteoinductive cytokine and
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widely used for alveolar bone regeneration. The results demonstrated that the transplantation of
BMP-2/β-TCP could accelerate the bone healing of tooth extraction sockets in both MRONJ prevention
and treatment models.
Recently, cell transplantation therapies using stem cells or differentiated/mature cells have been
performed not only for the treatment but also for prevention of diseases [28,29]. Kuroshima et al.
have reported that systematic transplantation of adipose tissue-derived stromal vascular fraction (SVF)
cells improved the bone necrotic lesions in the MRONJ-like mouse model [30]. Nevertheless, although
cell transplantation therapy is expected to be a breakthrough for the prevention of MRONJ, it is usually
costly and requires sophisticated management procedures.
Bone remodeling is a dynamic process involving resorption by osteoclasts and bone formation
by osteoblasts. BMP-2 is known to directly regulate the osteogenesis of immature osteoblasts or
progenitor cells by binding to the BMP receptor [18,31]. Moreover, BMP-2 is known to directly
enhance osteoclast differentiation from progenitor cells [19,20]. Therefore, it is assumed that BMP-2
can activate bone remodeling by having direct effects on both osteoblasts and osteoclasts, and could
be one major candidate cytokine for the prevention and treatment of MRONJ. Indeed, Brierly et al.
have reported that the transplantation of hydrogels loaded with BMP-2 (BMP-2/hydrogel) in the
tooth extraction socket prevented the onset of MRONJ in rats. However, the bone regeneration
rate promoted by BMP-2/hydrogel was moderate, i.e., the bone volume/total volume in the tooth
extraction sockets in the BMP-2/hydrogel group (69.1% ± 13.1%) increased only 1.36 times compared
to the non-transplantation group (50.9% ± 8.8%). Moreover, a detailed analysis of necrotic bone with
empty lacunae, which is one of the important parameters used to assess the severity of MRONJ,
was not performed [22]. Jung et al. have reported a clinical preliminary study showing that only
transplantation of BMP-2 absorbed with a collagen sponge (BMP-2/collagen) could not significantly
induce bone formation at the MRONJ site, compared with the non-transplantation group, and that PTH
administration would be necessary to stimulate the effect of BMP-2 in inducing bone formation [32].
These studies indicate that BMP-2 is an effective growth factor for MRONJ; however, its effectiveness
is still suboptimal. Therefore, in this study, we utilized the combination of BMP-2/β-TCP because
of the space-making capability of β-TCP, which allowed a 3.16-fold increase in the bone-fill rate
of 32.5% ± 17.2% compared with the non-transplantation group (10.3% ± 7.9%). In the MRONJ
treatment mouse model, transplantation of BMP-2/β-TCP after curettage in the tooth extraction socket
could completely regenerate the bone with blood vessels (Figure 3), previously atrophied by the
administration of angiogenesis suppressors, CY and ZA. These results suggest that the mechanical
and physico-chemical properties of β-TCP that allow for space making and bone remodeling are of
fundamental importance for bone regeneration in MRONJ, with superior effectiveness compared with
soft materials, such as hydrogels and collagen sponges.
Angiogenesis is a key process in the wound healing of various tissues including bone. Therefore,
the expression of EMCN, which is one of the vascular endothelial cell markers, was also analyzed in
a mouse model of MRONJ treatment. Surprisingly, although EMCN positive vascular endothelial
cells were observed at the healing site, the tooth extraction socket was not filled with newly-formed
bone in the control group. On the other hand, the transplantation of BMP-2/β-TCP after curettage
of the tooth extraction socket could promote a complete regeneration of the bone with blood vessels
(Figures 3 and 4). These data strongly indicate that not only activation of angiogenesis, but also
activation of bone turn-over using drugs or growth factors, like BMP-2, are essential for the treatment
of MRONJ patients.
Despite the promising bone-inducing effects of BMP-2, there are, however, important issues to be
considered when delivering BMP-2 to patients. For instance, an increasing number of studies have
reported complications, such as failure of bone regeneration and bone resorption associated with
the clinical use of the BMP-2 [33]. Jeppsson et al. had already reported in 1996 that bone healing is
inhibited by the treatment of BMP-2 in rabbits [34]; however, its mechanism remained unclear. Recently,
our research group has reported that while the transplantation of BMP-2 induced bone formation in the
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bone marrow-scarce environment (tooth extraction sockets and calvaria), it conversely induced bone
resorption in the bone marrow-abundant environments (mandible and femoral marrow) in vivo [35].
Additionally, we clarified that bone marrow cells inhibit BMP-2-induced osteoblast activity in vitro [35].
Therefore, special attention should be given to the characteristics of the host site where BMP-2 will be
transplanted. In this present study, BMP-2/β-TCP was transplanted into the bone-marrow scarce tooth
extracted sockets in both MRONJ-like prevention and treatment models, and therefore allowed an
effective bone augmentation.
In summary, we for the first time demonstrated that the transplantation of BMP-2 adsorbed in
β-TCP in the tooth extraction socket was effective for the prevention of the MRONJ onset, as well as for
the treatment of MRONJ symptoms in an MRONJ-like mouse model. Although further confirmation
using large animal models is required before application in the clinical setting, the results suggest that
transplantation therapies of BMP-2 adsorbed in β-TCP could become a suitable treatment for MRONJ.
4. Materials and Methods
4.1. Materials
To prepare the E-rhBMP2/β-TCP complex, 1.5 mg of β-TCP (Superpore, particle size 0.6–1.0 mm,
porosity 75%, HOYA, Tokyo, Japan) was immersed in 2.5 µL of 0.5 mM HCl containing 2.5 µg of BMP-2
(Osteopharma Inc., Osaka, Japan) and incubated for five minutes at room temperature. After incubation,
almost all the solution was absorbed in the porous of β-TCP.
4.2. Animal Model
C57BL/6J female mice (8 week-old to 12 week-old females) were purchased from CLEA Japan
Inc. (Tokyo, Japan). Recently, Kuroshima et al. [30,36] have reported that administration of CY and
ZA can induce an MRONJ-like conditions such as inhibition of bone regeneration and angiogenesis,
increased necrotic bone with empty lacuna in the tooth extraction sockets of mice. Therefore, in this
study, MRONJ-like model mice were prepared according to their method [36]. Briefly, to create the
MRONJ-like model, both zoledronate (ZA, 0.05 mg/kg, Zometa; Novartis, Stein, Switzerland) and
cyclophosphamide (CY, 100 mg/kg, C7397; Sigma-Aldrich, St. Louis, MO, USA) were administrated
subcutaneously and intraperitoneally, respectively, twice a week for 3 weeks. Three weeks after CY
and ZA administration, the maxillary first molars were extracted under general anesthesia. After tooth
extraction, MRONJ prevention and treatment models were designed.
In the case of the MRONJ prevention model, E-rhBMP2/β-TCP was transplanted into tooth
extraction sockets immediately after tooth extraction. After transplantation, both CY and ZA were
continuously administered twice a week for 4 weeks.
In the MRONJ treatment model, both CY and ZA were administered twice a week for 2 weeks
after tooth extraction. The tooth extraction sockets were curetted by a dental probe and BMP-2/β-TCP
was transplanted into the tooth extraction sockets. No medicine was administered in the subsequent
four weeks. The control groups received no transplantation.
The animal experiment protocols used in this study (OKU-2019254, OKU-2020380) were approved
by the Okayama University Animal Research Committee. All animals were handled according to the
guidelines of the Okayama University Animal Research Committee.
4.3. Micro Computed Tomography (Micro-CT) Analysis
The collected samples were fixed with 4% paraformaldehyde (PFA; Merck, Kenilworth, NJ, USA)
and analyzed by using a micro-computed tomography (micro-CT, SkyScan 1174, Bruker, Kontich,
Belgium) as described previously [35]. The micro-CT parameters were as follows: 6.5 µm voxel size,
50 kVp, 800 µA, 1 mm aluminum filter, angular rotation step 0.7◦, 180◦ scanning, 261 projections, and an
exposure time of 4 s with a total scan duration of 37 min. Transmission images were reconstructed
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using SkyScan NReconc software (Bruker, Kontich, Belgium), and 2D images were obtained with
SkyScan Data Viewer software (Bruker, Kontich, Belgium).
4.4. Histological Analysis
Fixed samples were decalcified with Morse solution (Shiyaku, Kyoto, Japan) for 1 week and
embedded in paraffin. Sections of 5 µm were stained with Hematoxyline and Eosin (HE) and Masson’s
trichrome according to standard protocols.
For immunohistochemical (IHC) analysis, frozen sections were prepared by using the Kawamoto’s
film method, according to a previous report [37]. Briefly, samples fixed with 4% PFA were
freeze-embedded in super cryoembedding medium (SECTION-LAB Co., Ltd., Hiroshima, Japan) and
cut into widths of 5 µm with a tungsten carbide blade using an adhesive film. In addition, sections were
blocked with 5% goat serum (Life technologies, Gaithersburg, MD, USA) for 60 min at room temperature
(RT) and incubated with anti-osteopontin antibody (OPN: Immuno-Biological Laboratories, Gunma,
Japan) and anti-endomucin antibody (EMCN: sc-65495, Santa Cruz Biotechnology, Dallas, TX, USA)
overnight at 4 ◦C. Sections were washed and incubated with the secondary antibody, Alexa Fluor
488 goat anti-rabbit IgG or Alexa Fluor 647 goat anti-rat IgG (Life technologies, Gaithersburg, MD,
USA) for 1 h at RT in a dark chamber. All images were taken with a BZ-710 fluorescence microscope
(Keyence, Osaka, Japan) and quantitative analyses of bone-fill rate, the number of empty osteocyte
lacunae, rate of collagen fiber into the remaining connective tissue and rate of OPN positive area and
EMCN positive vessel area in the tooth extraction sockets were performed using the BZ analyzer
(Keyence, Osaka, Japan).
5. Statistic Analysis
The results obtained from quantitative experiments were reported as the mean values ± SD.
Statistical analyses were performed with two-way factorial ANOVA followed by Tukey’s multiple
comparison tests and the unpaired Student’s t-test.
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